The co-heads of private equity firm Cinven, Jorge Quemada and Bruno Schick, presented a united front in their first joint interview since a regulatory scandal led to the resignation of former CEO Supraj Rajagopalan. Wearing matching blue shirts, they emphasized stability and compliance following a £52mn fine upheld by a court for Cinven’s role in illegally increasing NHS drug prices. The firm, managing €45bn in assets, faced criticism over its handling of Italian insurer Eurovita and a shift to three co-managing partners in 2024.

Quemada and Schick said they restored investor confidence through transparency and clear leadership during the Competition and Markets Authority investigation. Cinven is closing a €1.5bn midsized buyout fund and plans a flagship fundraise next year. Recent exits include a €29bn sale of TK Elevator with Advent and a €10bn exit of Stada with Bain Capital, returning 30% of holdings’ value to investors — double the industry average.

To prevent recurrence, Cinven has trained teams, upgraded due diligence, and built a 17-person internal legal and compliance team, absent during its 2012 drugmaker investment.